Lenalidomide + EPOCH Chemotherapy for Adult T-Cell Leukemia-Lymphoma
Trial Summary
The trial protocol does not specify if you need to stop taking your current medications. However, you cannot use other chemotherapy, interferon, zidovudine, arsenic, radiation therapy, or specific anti-tumor therapy during the study.
The modified EPOCH regimen, which includes some of the same drugs as the Lenalidomide + EPOCH combination, has shown effectiveness in treating aggressive adult T-cell leukemia/lymphoma, with patients achieving complete or partial remission. Additionally, lenalidomide has been approved for use in relapsed or refractory cases of this disease, suggesting potential benefits when combined with EPOCH chemotherapy.
12345The EPOCH chemotherapy regimen, which includes drugs like cyclophosphamide, doxorubicin, etoposide, vincristine, and prednisone, has been studied for various lymphomas and leukemia. Common side effects include low blood cell counts, nausea, vomiting, constipation, and infections, but these are generally manageable with supportive care. Lenalidomide, used for T-cell lymphomas, has manageable toxicity, with serious side effects mainly affecting blood cells, but these are reversible.
678910This treatment combines lenalidomide, which has unique immune-boosting and anti-cancer effects, with the EPOCH chemotherapy regimen, potentially offering a novel approach for aggressive adult T-cell leukemia-lymphoma, especially for patients who may not respond well to standard therapies.
19111213Eligibility Criteria
This trial is for adults with T-cell leukemia-lymphoma, including those untreated or with one prior chemo cycle. Participants must have adequate organ function, no serious infections, and a life expectancy over 12 weeks. HIV-positive patients on effective therapy can join; hepatitis C must be treated. Pregnant women cannot participate, and all participants must use birth control.Inclusion Criteria
Exclusion Criteria